
Regulus’ shares drop as FDA puts trials for hepatitis C drug on hold
pharmafile | June 29, 2016 | News story | Research and Development, Sales and Marketing |Â Â Regulus Therapeutics, US FDA, drug trial, hepatitis C virus, regulationÂ
Shares in Regulus Therapeutics (Nasdaq: RGLS) plunged as much as 60% after the company said the US Food and Drug Administration (FDA) has put on hold trials for its drug compound to treat chronic hepatitis C virus.
The company said the regulator initiated the clinical hold following the report of a second serious adverse event of jaundice in a patient with end-stage renal disease on dialysis enrolled in an ongoing Phase I study of RG-101.
The adverse event occurred 117 days after receiving a single dose of RG-101, the company said.
Regulus said the timelines for three ongoing studies of RG-101 are not expected to be impacted as all patients have completed their dosing.
About 130–150 million people in the world have chronic hepatitis C infection, a liver disease that can cause liver cirrhosis or liver cancer, according to statistics.
Anjali Shukla
Related Content

‘Smart drugs’ may contain unapproved pharmaceuticals, according to a new study
Some supplements billed as ‘smart drugs’ may contain unapproved drugs in potentially dangerous combinations and …

COVID-19: UK and Europe life sciences regulatory developments
Marie Manley, Partner, and Bethany Wise, Trainee Solicitor, at Sidley Austin look at UK and …

Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug
Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders …






